Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman

Some of our 2018 predictions on consolidation, pharma, and investment came true, while others were less predictable.

Principal, Oliver Wyman

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Engagement Manager, Oliver Wyman

As merger activity heightens, some leverage retail with pharma to meet consumer demand.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Oliver Wyman
Senior Consultant, Health & Life Sciences, Oliver Wyman

Once J.P. Morgan Healthcare Week comes to a close, companies will need to show as much as they tell.

Chief Strategist, Health Practice, Edelman

Insights in your inbox

Subscribe

Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.

Seeing a return on investment in pharma marketing means understanding what happens to every dollar.

Engagement Manager, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Digital & Analytics, Oliver Wyman

Those challengers who address critical patient needs beyond traditional treatment will become a force to be reckoned with.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

From Walmart to Amazon to 23andMe, these 11 market scenarios paint a picture of what disruption looks like, both in and out of healthcare.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Chief Strategy Officer, BCBS of Massachusetts
Principal, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe